Company / Shareholders' Equity
FATE THERAPEUTICS INC Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$318.7M
FY2025
5-year range
$244.8M / $678.8M
FY2021-FY2025
Trend
-13.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 3 consecutive years, from $679M in FY2022 to $319M in FY2025.
Based on SEC 10-K filings.
$319M in FY2025 with a 5-year CAGR of +14.7%.
Declined from $484M to $319M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -22.3%
- 5-Year CAGR
- +14.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- FATE THERAPEUTICS INC's shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of +14.7%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 13.5% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $318.7M | -13.5% |
| FY2024 | $368.4M | -23.9% |
| FY2023 | $483.9M | -28.7% |
| FY2022 | $678.8M | +177.4% |
| FY2021 | $244.8M | +52.5% |
| FY2020 | $160.5M | +107.9% |
| FY2019 | $77.2M | +5.5% |
| FY2018 | $73.2M | +92.3% |
| FY2017 | $38.0M | +34.2% |
| FY2016 | $28.3M | -44.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026